Akoya Biosciences, which provides spatial biology solutions for discovery and clinical research, raised $132 million by offering 6.6 million shares at $20, the high end of the range of $18 to $20. At pricing, the company commands a fully diluted market value of $793 million.
Akoya delivers spatial biology solutions focused on transforming discovery and clinical research. Through its CODEX and Phenoptics platforms, reagents, software and services, the company offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum, from discovery through translational and clinical research. As of December 31, 2020, Akoya had over 550 instruments installed across customers throughout North America, Europe, and APAC, a +27% increase over 2019.
Akoya Biosciences plans to list on the Nasdaq under the symbol AKYA. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity acted as lead managers on the deal.
